Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017, Article ID 1606854, 6 pages
https://doi.org/10.1155/2017/1606854
Research Article

OM-101 Decreases the Fibrotic Response Associated with Proliferative Vitreoretinopathy

Kaplan Medical Center-Rehovot, Affiliated to Hadassah-Hebrew University of Jerusalem, Rehovot, Israel

Correspondence should be addressed to Ayala Pollack; moc.liamg@alaya.kcallop

Received 17 March 2017; Accepted 6 September 2017; Published 4 October 2017

Academic Editor: Glenn Yiu

Copyright © 2017 Zeev Dvashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. G. Charteris, “Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment,” The British Journal of Ophthalmology, vol. 79, no. 10, pp. 953–960, 1995. View at Publisher · View at Google Scholar · View at Scopus
  2. O. W. Kwon, M. I. Roh, and J. H. Song, “Retinal detachment and proliferative vitreoretinopathy,” Developments in Ophthalmology, vol. 55, pp. 154–162, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. J. G. Garweg, C. Tappeiner, and M. Halberstadt, “Pathophysiology of proliferative vitreoretinopathy in retinal detachment,” Survey of Ophthalmology, vol. 58, no. 4, pp. 321–329, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. P. J. Banerjee, M. G. Woodcock, C. Bunce, R. Scott, and D. G. Charteris, “A pilot study of intraocular use of intensive anti-inflammatory; triamcinolone acetonide to prevent proliferative vitreoretinopathy in eyes undergoing vitreoretinal surgery for open globe trauma; the adjuncts in ocular trauma (AOT) trial: study protocol for a randomised controlled trial,” Trials, vol. 14, p. 42, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Takahashi, O. Nagano, T. Ishimoto et al., “Tumor necrosis factor-α regulates transforming growth factor-β-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction,” The Journal of Biological Chemistry, vol. 285, no. 6, pp. 4060–4073, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. E. Zhang, “Non-Smad pathways in TGF-β signaling,” Cell Research, vol. 19, no. 1, pp. 128–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Mu, S. K. Gudey, and M. Landstrom, “Non-Smad signaling pathways,” Cell and Tissue Research, vol. 347, no. 1, pp. 11–20, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Dvashi, M. Goldberg, O. Adir, M. Shapira, and A. Pollack, “TGF-β1 induced transdifferentiation of rpe cells is mediated by TAK1,” PLoS One, vol. 10, no. 4, article e0122229, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Wu, F. Powell, N. A. Larsen et al., “Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol,” ACS Chemical Biology, vol. 8, no. 3, pp. 643–650, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. V. Canto Soler, J. E. Gallo, R. A. Dodds, and A. M. Suburo, “A mouse model of proliferative vitreoretinopathy induced by dispase,” Experimental Eye Research, vol. 75, no. 5, pp. 491–504, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. Z. Dvashi, H. J. Shalom, M. Shohat et al., “Protein phosphatase magnesium dependent 1A governs the wound healing-inflammation-angiogenesis cross talk on injury,” The American Journal of Pathology, vol. 184, no. 11, pp. 2936–2950, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Tan, Y. Liu, W. Li, and Q. Gao, “Ocular pathogenesis and immune reaction after intravitreal dispase injection in mice,” Molecular Vision, vol. 18, pp. 887–900, 2012. View at Google Scholar
  13. S. Tamiya, L. Liu, and H. J. Kaplan, “Epithelial-mesenchymal transition and proliferation of retinal pigment epithelial cells initiated upon loss of cell-cell contact,” Investigative Ophthalmology & Visual Science, vol. 51, no. 5, pp. 2755–2763, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Lamouille and R. Derynck, “Cell size and invasion in TGF-β-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway,” The Journal of Cell Biology, vol. 178, no. 3, pp. 437–451, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. S. H. Conner, G. Kular, M. Peggie et al., “TAK1-binding protein 1 is a pseudophosphatase,” The Biochemical Journal, vol. 399, no. 3, pp. 427–434, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Saika, O. Yamanaka, K. Ikeda et al., “Inhibition of p38MAP kinase suppresses fibrotic reaction of retinal pigment epithelial cells,” Laboratory Investigation, vol. 85, no. 7, pp. 838–850, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Kalluri and R. A. Weinberg, “The basics of epithelial-mesenchymal transition,” The Journal of Clinical Investigation, vol. 119, no. 6, pp. 1420–1428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. K. Parapuram, B. Chang, L. Li et al., “Differential effects of TGFβ and vitreous on the transformation of retinal pigment epithelial cells,” Investigative Ophthalmology & Visual Science, vol. 50, no. 12, pp. 5965–5974, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Sugioka, A. Kodama, K. Okada et al., “TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression,” Experimental Eye Research, vol. 115, pp. 13–21, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. H. M. Lambert, R. Diaz-Rohena, F. J. LoRusso, and J. W. Thomas, “Current management of proliferative vitreoretinopathy,” Seminars in Ophthalmology, vol. 10, no. 1, pp. 49–52, 1995. View at Publisher · View at Google Scholar · View at Scopus